Compare Neurocrine Biosciences Inc (NBIX) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Victoria's Secret & Co — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while Victoria's Secret & Co trades at $82.87 (market cap $6.91B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.1× Victoria's Secret & Co's market cap, and Victoria's Secret & Co is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Victoria's Secret & Co for 34 Days on average.
| NBIX | VSXY | |
|---|---|---|
Market Cap | $14.36B | $6.91B |
Volume | 1,237,180 | 1,346,928 |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $99.97 |
52-Week Low | $123.10 | $28.25 |
Typical Hold Time | 23 Days | 34 Days |
Enterprise Value | $14.37B | $9.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
Victoria's Secret (VSXY) trades at $86.61, up 0.96% with a bullish technical signal and strong analyst support. The stock shows improving fundamentals with three consecutive earnings beats and projected 2026 revenue growth to $6.9B. Recent news highlights brand momentum through fashion show expansion and omnichannel retail strategy driving international growth.
The outlook appears positive with 60% analyst buy ratings and $86.80 consensus target, though rich valuation (P/E 19.33) and rising costs present risks. Key catalysts include sustained margin improvement and global expansion execution, while competition and demand volatility remain concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
